01—Abstract
Summary
Summary of the 8-K filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported third quarter 2026 results on October 29, 2026, with total revenues, net of $353.2 million, compared to $120.7 milliona in the third quarter of 2025.
The increase was driven primarily by U.S. Attruby net product revenue of $253.2 millionb and a $75.0 million sales milestone from Bayer under the Bayer License Agreement recognized in the quarter. The company reported a loss from operations of $11.6 million and a net loss attributable to common stockholders of $83.0 million, or $0.42 per share, compared to $182.7 million, or $0.95 per share, a year earlier. Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026, up from $587.5 million at December 31, 2025, which the company says will fund its three potential launches and expansion indications.
The company highlighted three PDUFA dates within roughly seven months: BBP-418 for LGMD2I/R9 on November 27, 2026, oral infigratinib for achondroplasia on February 4, 2027, and encaleret for ADH1 on May 8, 2027, each with Priority Review. Encaleret also began Phase 3 RECLAIM-HP in chronic hypoparathyroidism, with topline data expected in early 2028. Total operating costs and expenses rose to $364.8 millionc, driven by higher SG&A spending on commercialization and pre-commercial launch activities, and by higher R&D spending.
The company also reported real-world evidence for acoramidis versus tafamidis, including an 18% lower risk of a composite outcome in an Epic COSMOS analysis of 2,684 patients, and new cardiac MRI data from ATTRibute-CM and its extension. Operating expenses and other expense, net of $47.6 milliond weighed on results, and the filing notes preferred stock dividends and accretion of $26.3 million in the quarter.
02—Key points
Key Highlights
- Total revenues, net of $353.2 million for Q3 2026, versus $120.7 million in Q3 2025, including a $75.0 million Bayer sales milestone recognized in the quarter.
- U.S. Attruby net product revenue of $253.2 million, up approximately $31 million sequentially and $145 million year over year.
- Loss from operations narrowed to $11.6 million from $145.2 million a year earlier; net loss attributable to common stockholders was $83.0 million, or $0.42 per share.
- Cash, cash equivalents and marketable securities of $1.5 billion at September 30, 2026, versus $587.5 million at December 31, 2025.
- Three Priority Review PDUFA dates: BBP-418 (November 27, 2026), oral infigratinib (February 4, 2027), and encaleret for ADH1 (May 8, 2027).
- Total operating costs and expenses rose to $364.8 million, led by a $63.2 million increase in SG&A and a $30.6 million increase in R&D.
- Series A preferred stock issuance of $933.9 million in proceeds during the nine months, alongside $632.5 million of 2033 Notes proceeds.
03—Questions
Frequently Asked Questions
What drove the increase in revenue this quarter?
Total revenues, net rose $232.5 million to $353.2 million, primarily due to a $145.2 million increase in Attruby net product revenue and a $71.1 million increase in license and services revenue. The license and services increase reflects recognition of a $75.0 million sales milestone under the Bayer License Agreement achieved in the third quarter of 2026. Royalty revenue, mainly from BEYONTTRA sales in the EU and Japan, rose $16.2 million.
What are the near-term regulatory catalysts?
BBP-418 for LGMD2I/R9 has a PDUFA date of November 27, 2026, with no advisory committee meeting currently planned. Oral infigratinib for achondroplasia has a PDUFA date of February 4, 2027, and its MAA is under EMA review with potential EU approval in the second half of 2027. Encaleret for ADH1 has a PDUFA date of May 8, 2027, and its MAA is also under EMA review.
Why did the net loss per share narrow compared with last year?
The net loss attributable to common stockholders was $83.0 million, or $0.42 per share, versus $182.7 million, or $0.95 per share, in the third quarter of 2025. The loss from operations improved to $11.6 million from $145.2 million, driven by higher revenue. The filing also notes preferred stock dividends and accretion of $26.3 million in the current quarter, which partly offset the improvement.
How is the company funding its launches and expanded pipeline?
Cash, cash equivalents and marketable securities reached $1.5 billion at September 30, 2026. During the nine months, the company received $933.9 million from issuance of preferred stock and $632.5 million from issuance of 2033 Notes. Net cash used in operating activities was $312.6 million for the nine months. The company states its cash is expected to fund its three potential launches and expansion indications.
What did the company report on Attruby's real-world evidence?
The company cited an independent Epic COSMOS analysis of 2,684 patients, which found an 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation and diuretic intensification versus tafamidis (HR 0.82; p<0.01). A separate peer-reviewed U.S. claims study found a 34% reduction in composite clinical worsening with acoramidis (HR 0.66; p=0.046). New ESC data showed clinically meaningful improvement in left ventricular systolic function in 54% of acoramidis-treated participants versus 20% of placebo at Month 30.
04—Continue